An Open-Label Study Evaluating the Safety and Tolerability of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2018
At a glance
- Drugs Pancreatic beta cell replacement therapy-ViaCyte (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors ViaCyte
- 17 Oct 2018 Status changed from active, no longer recruiting to completed.
- 03 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 07 Jul 2017 Status changed from not yet recruiting to recruiting.